New collaboration exemplifies combined commitment to improve patient safety and confidence
Noble®, a leader in biopharmaceutical onboarding and device training, today announces a global collaboration with BD (Becton, Dickinson and Company), a leading global medical technology company, for developing patient onboarding solutions including demonstration devices.
Through this collaboration, Noble will leverage its onboarding training solutions to develop novel demonstrators based on the BD UltraSafe™ technology that will enable broader access to new services for pharmaceutical partners to support product launches and to improve patient experience and confidence. The combination of Noble’s expertise in user market research and BD’s technology developed in passive needle stick safety devices allows commercialization teams to fully customize drug delivery devices and have access to dedicated onboarding systems all in one place.
“Demonstration devices can be instrumental in helping patients overcome fear and anxiety when using an injectable drug delivery device. However, our research has shown that for onboarding to be successful, the demonstrating device must be meticulously engineered to mimic the exact look and feel of the actual drug delivery device,” said Craig Baker, executive vice president at Noble. “In a recent market survey, we found that 89 percent of patients reported it’s very important to have the most realistic demonstrating device possible. By having a deep understanding of complex device engineering and patient needs, we can better help our partners like BD create impactful onboarding solutions.”
Noble adheres to a strict quality control process to ensure partners are providing patients with first-class demonstration devices. All demonstrators are tested to guarantee needle simulation and plunger speeds accurately mimic those of real drug delivery devices. This process may also improve speed to market and the launch process overall.
“This collaboration represents the latest commitment to our ongoing expansion of the BD UltraSafe™ Needle Guard portfolio, as BD continues to increase the capabilities of the platform within the injectable biopharmaceutical market,” said Patrick Jeukenne, vice president of safety and shielding systems for BD. “With the increased use of the BD UltraSafe Passive™ and BD UltraSafe Plus™ Passive Needle Guards by patients who self-inject doctor prescribed medications, there is a need to provide a solution to our pharmaceutical partners to support patient onboarding. Noble’s systems deliver a viable option that leverages strong expertise for patients and broadens BD’s overall offering in demonstration devices.”